Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)
Journal of Clinical Oncology · 20.06.2024 · 42 (18) · 2161-2173
DOI: 10.1200/jco.23.01599 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.06.2024. Verfasst von Ing Soo Tiong und 19 weiteren Autor:innen. Beteiligte Einrichtung: The Alfred Hospital and Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Neoplasm, Residual, Cytarabine, Sulfonamides. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE A prospective phase II study examined the safety and efficacy of venetoclax combined with low-dose cytarabine (LDAC) in AML at first measurable residual disease (MRD) or oligoblastic relapse. METHODS Patients with either MRD (≥1 log 10 rise) or oligoblastic relapse (blasts 5%-15%) received venetoclax 600 mg once daily D1-28 plus LDAC once daily D1-10 in 28-day cycles. The primary objective was MRD response in the MRD relapse cohort or complete remission (CR/CRh/CRi) in the oligoblastic relapse cohort. RESULTS Forty-eight adults with either MRD (n = 26) or oligoblastic (n = 22) relapse were enrolled. Median age was 67 years (range, 18-80) and 94% had received previous intensive chemotherapy. Patients received a median of four cycles of therapy; 17% completed ≥12 cycles. Patients with oligoblastic relapse had more grade ≥3 anemia (32% v 4%; P = .02) and infections (36% v 8%; P = .03), whereas grade 4 neutropenia (32 v 23%) or thrombocytopenia (27 v 15%) were comparable with the MRD relapse cohort. Markers of molecular MRD relapse included mutant NPM1 (77%), CBFB::MYH11 (4%), RUNX1::RUNX1T1 (4%), or KMT2A::MLLT3 (4%). Three patients with a log 10 rise in IDH1/ 2 (12%) were included. By cycle 2 in the MRD relapse cohort, a log 10 reduction in MRD was observed in 69%; 46% achieved MRD negative remission. In the oligoblastic relapse cohort, 73% achieved CR/CRh/CRi. Overall, 21 (44%) underwent hematopoietic cell transplantation. Median overall survival (OS) was not reached in either cohort. Estimated 2-year OS rate was 67% (95% CI, 50 to 89) in the MRD and 53% (95% CI, 34 to 84) in the oligoblastic relapse cohorts. CONCLUSION For AML in first remission and either MRD or oligoblastic relapse, venetoclax plus LDAC is well tolerated and highly effective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Alfred Hospital and Monash University, Melbourne, Australia.
- Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia.
- Royal Adelaide Hospital, Adelaide, Australia.
- University of Adelaide, Adelaide, Australia.
- South Australian Health and Medical Research Institute, Adelaide, Australia.
- Princess Alexandra Hospital, Queensland, Australia.
ORCID-Profile: Ing Soo Tiong, Ashish Bajel, John Reynolds, Natasha Anstee, Sun Loo, Chong Chyn Chua, Michael Ashby, Chun Y Fong, Richard Dillon, Andrew H Wei
Zitieren
APA
Tiong, I. S., Hiwase, D. K., Abro, E., Bajel, A., Palfreyman, E., Beligaswatte, A., Reynolds, J., Anstee, N., Nguyen, T., Loo, S., Chua, C. C., Ashby, M., Wiltshire, K. M., Fleming, S., Fong, C. Y., Teh, T. C., Blombery, P., Dillon, R., Ivey, A., & Wei, A. H. (2024). Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC). Journal of Clinical Oncology, 42(18), 2161-2173. https://doi.org/10.1200/jco.23.01599
Vancouver
Tiong IS, Hiwase DK, Abro E, Bajel A, Palfreyman E, Beligaswatte A, et al. Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC). Journal of Clinical Oncology. 2024;42(18):2161-2173. doi:10.1200/jco.23.01599
BibTeX
@article{Tiong2024,
author = {Tiong, Ing Soo and Hiwase, Devendra K and Abro, Emad and Bajel, Ashish and Palfreyman, Emma and Beligaswatte, Ashanka and Reynolds, John and Anstee, Natasha and Nguyen, Tamia and Loo, Sun and Chua, Chong Chyn and Ashby, Michael and Wiltshire, Kaitlyn M and Fleming, Shaun and Fong, Chun Y and Teh, Tse-Chieh and Blombery, Piers and Dillon, Richard and Ivey, Adam and Wei, Andrew H},
title = {Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {18},
pages = {2161--2173},
doi = {10.1200/jco.23.01599}
}
EUVIMED